Oligonucleotide CMC Strategies
After the first oligonucleotide therapeutic was approved in 1998, almost 20 oligonucleotide drugs have reached the market (2). Considering the...
Introduction
CMC Control Strategies and Impurity Evaluation for Complex and Emerging Oligonucleotide Therapeutics
Considerations and Strategies for Oligonucleotide Manufacturing Scale-Up
Development of Kilogram-Scale Convergent Liquid-Phase Synthesis of Oligonucleotides:
Novel thiomorpholino oligonucleotides (TMOs) as a robust next generation platform for spice switching antisense therapies
High-efficiency Nucleic Acid Manufacturing Systems to Fulfil the Promise of Genomic Medicine:
Refractive Index as a PAT Tool to Monitor Solid Phase Oligonucleotide Synthesis